Delayed xenograft rejection. Immunol Today 17, 379 -384 (1996). 15 Report PEL -TR-0002.00: Comparison of functional activity of Human, Mouse and Cynomolgus OX40L. 29-October -2018. 16 Report HBI -18-0007.02: Acute cytokine release, si ngle high dose-escalation safety study, in mouse, with using mouse HS -130 cells, human HS-130 cells and anti -OX40 agonist antibody (HRG#099). 18 -April - 2019. 17 Report HBI -19-0019.01: Gp96-Ig (mHS -110) to OX40L-Ig (mHS -130) variable ratio, dose -escalation, MABEL determination in tumor -bearing animals (HRG#106). 13 -May -2019. Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 58 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page APPENDIX I - ECOG Performance Status Grade 0 Fully active, able to carry on all pre -disease performance without restriction. 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework , office work.